Eur J Endocrinol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


DOI: 10.1530/eje.0.1450335
European Journal of Endocrinology, Vol 145, Issue 3, 335-341
Copyright © 2001 by European Society of Endocrinology
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wachenfeld, C
Right arrow Articles by Reincke, M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wachenfeld, C
Right arrow Articles by Reincke, M

Articles

Discerning malignancy in adrenocortical tumors: are molecular markers useful?

C Wachenfeld, F Beuschlein, O Zwermann, P Mora, M Fassnacht, B Allolio, and M Reincke

Schwerpunkt Endokrinologie, Medizinische Universitatsklinik Wurzburg, Wurzburg, Germany.

OBJECTIVE: Adrenocortical carcinoma (ACC) is a rare neoplasm with poor prognosis. Discerning ACCs from benign adenomas histologically may be difficult if invasion into surrounding tissues or metastases are missing. DESIGN: In order to establish molecular markers for malignancy, we analyzed seven normal adrenals, three massive macronodular ACTH-independent adrenocortical hyperplasias (MMAHs), 30 adrenocortical adenomas (ACAs) and ten ACCs. METHODS: All tissues were studied for the presence of alterations in the p53 tumor suppressor gene using the PAb 1801 antibody, which detects mutant p53 protein and the pYNZ22 microsatellite marker to show loss of heterozygosity (LOH) at 17p, for expression of the proliferation-associated antigen Ki67 using the MIB1 antibody, for the rate of apoptotic tumor cells with the TdT-mediated dUTP biotin nick end labeling (TUNEL) method, and for LOH of 11q13 (menin gene locus) with the D11S956 microsatellite marker. RESULTS: 0/3 MMAH, 1/28 ACA and 3/10 ACC revealed immunopositive staining for p53. LOH for pYNZ22 was observed in 1/3 MMAH, 1/23 informative ACA and 6/6 informative ACC. The rate of apoptotic cells was significantly higher in ACC (P<0.0001 by ANOVA) than in ACA but there was some overlap between groups. The Ki67 index (% immunopositive cells) was 1.9+/-1.30% (mean+/-s.d.) in normal adrenals, 3.47+/-1.37% in MMAH, and 2.11+/-1.01% in ACA. ACC had the highest Ki67 index of 11.94+/-7.58% distinguishing all ACC from the ACA and MMAH studied with a cut-off level of 5%. LOH for 11q13 was detected in 2/3 MMAH, 5/26 ACA and 6/8 ACC. CONCLUSIONS: We conclude that a Ki67 index above 5% is a sensitive and specific indicator of ACC and may be useful in the differentiation of adenomas from carcinomas.


This article has been cited by other articles:


Home page
J. Clin. Pathol.Home page
A Advani, S Vaikkakara, M S Gill, C S Arun, S H Pearce, S G Ball, R A James, T W J Lennard, R D Bliss, R Quinton, et al.
Impact of standardised reporting in adrenocortical carcinoma: a single centre clinicopathological review
J. Clin. Pathol., August 1, 2008; 61(8): 939 - 944.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
I G C Hermsen, H Gelderblom, J Kievit, J A Romijn, and H R Haak
Extremely long survival in six patients despite recurrent and metastatic adrenal carcinoma.
Eur. J. Endocrinol., June 1, 2008; 158(6): 911 - 919.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
B. Allolio and M. Fassnacht
Adrenocortical Carcinoma: Clinical Update
J. Clin. Endocrinol. Metab., June 1, 2006; 91(6): 2027 - 2037.
[Abstract] [Full Text] [PDF]


Home page
Vet PatholHome page
P. Labelle, A. E. Kyles, T. B. Farver, and H. E. V. De Cock
Indicators of Malignancy of Canine Adrenocortical Tumors: Histopathology and Proliferation Index
Vet. Pathol., September 1, 2004; 41(5): 490 - 497.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
G. Mansmann, J. Lau, E. Balk, M. Rothberg, Y. Miyachi, and S. R. Bornstein
The Clinically Inapparent Adrenal Mass: Update in Diagnosis and Management
Endocr. Rev., April 1, 2004; 25(2): 309 - 340.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
P. Luciani, P. Ferruzzi, G. Arnaldi, C. Crescioli, S. Benvenuti, G. Nesi, A. Valeri, I. Greeve, M. Serio, M. Mannelli, et al.
Expression of the Novel Adrenocorticotropin-Responsive Gene Selective Alzheimer's Disease Indicator-1 in the Normal Adrenal Cortex and in Adrenocortical Adenomas and Carcinomas
J. Clin. Endocrinol. Metab., March 1, 2004; 89(3): 1332 - 1339.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
M.-H. Bernard, S. Sidhu, N. Berger, J.-L. Peix, D. J. Marsh, B. G. Robinson, V. Gaston, Y. Le Bouc, and C. Gicquel
A Case Report in Favor of a Multistep Adrenocortical Tumorigenesis
J. Clin. Endocrinol. Metab., March 1, 2003; 88(3): 998 - 1001.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
T. J. Giordano, D. G. Thomas, R. Kuick, M. Lizyness, D. E. Misek, A. L. Smith, D. Sanders, R. T. Aljundi, P. G. Gauger, N. W. Thompson, et al.
Distinct Transcriptional Profiles of Adrenocortical Tumors Uncovered by DNA Microarray Analysis
Am. J. Pathol., February 1, 2003; 162(2): 521 - 531.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
C. A. Koch, K. Pacak, and G. P. Chrousos
The Molecular Pathogenesis of Hereditary and Sporadic Adrenocortical and Adrenomedullary Tumors
J. Clin. Endocrinol. Metab., December 1, 2002; 87(12): 5367 - 5384.
[Abstract] [Full Text] [PDF]


Home page
Ann. N. Y. Acad. Sci.Home page
I. BOURDEAU and C. A. STRATAKIS
Cyclic AMP-Dependent Signaling Aberrations in Macronodular Adrenal Disease
Ann. N.Y. Acad. Sci., June 1, 2002; 968(1): 240 - 255.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 European Society of Endocrinology.